Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Seroquel (Quetiapine) – US: CAFC: Sometimes, sins of omission are not inequitable conduct: AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA, Inc (Patent Docs) (Patent Baristas) (GenericsWeb)

Biotech legislative agenda: healthcare, energy, patents and capital (IP Watch)

India: Applying for patents does pay: Wockhardt wins kudos from the Indian government (SPICY IP)

US: CAFC ruling in Board of Trustees of the Leland Stanford Junior University et al v Roche Molecular Systems et al – How to lose a patent? Have the inventor make a secret side deal (Patent Baristas)

US: Governors send letter to Congressional leaders in support of 12-year data exclusivity period (Patent Docs)

US Congress urged to act on biosimilars (GenericsWeb)

US: Hal Wegner wakes up ACI Biotech Patents Forum in Boston – KSR and biotech claims (BioTechnology Patent Law)

Amrix (Cyclobenzaprine) – US: Eurand files patent infringement suit in C D California against Anchen following Para IV challenge (Patent Docs)

Avonex (human interferon beta 1a) – US: Biogen Idec receives method-of-use patent on human ß-interferon – implications for patent protection for Avonex (Patent Docs)

Fentora (Fentanyl) – US: Cephalon files patent infringement suit against Watson following Para IV challenge (Patent Docs)

Lexapro (Escitalopram) – US: Caraco closes asset purchase agreement with Forest Laboratories to settle Lexapro ANDA patent litigation (SmartBrief)

Losartan – Netherlands: Losartan and third party oppositions in the Netherlands (The SPC blog)

Losartan – UK: EWCA rules on Losartan paediatric extension: E I du Pont Nemours & Co v UK IPO (The SPC blog)

Losartan– Latvia: Latvian Patent Office publishes notice regarding issue of paediatric extension for Losartan (The SPC blog)

Mircera (Methoxy polyethylene glycol-epoetin beta) – Obviousness-type double patenting after Amgen v. F. Hoffmann-La Roche (Patent Docs)

Razadyne (Galanthamine) – US: CAFC: You can’t rely on test results that weren’t available when your patent application was filed: Janssen Pharma and Synaptech v. Teva, Mylan, Dr. Reddy’s, Barr and Purepac (Patent Baristas)

Renagel (Sevelamer) – US: Genzyme files patent infringement suit against Endo Pharmaceuticals following Para IV challenge (Patent Docs)

Roundup Ready cotton seed – US: Monsanto files patent infringement suits against Brent M Hargrove and Larry H Lytle based on defendants’ use of cotton seed produced from earlier planted Roundup Ready cotton seed (Patent Docs)

Seroquel (Quetiapine) – US: CAFC: Sometimes, sins of omission are not inequitable conduct: AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA, Inc (Patent Docs) (Patent Baristas) (GenericsWeb)

Trileptal (Oxacarbazepine) – Israel Patent Office prevents Novartis from submitting empirical evidence in patent opposition case (IP Factor)

Vesicare (Solifenacin) – US: Astellas files patent infringement lawsuit against Teva over generic Vesicare (GenericsWeb)

Zyprexa (Olanzapine) – Canada: Teva Novopharm invalidates Eli Lilly’s Canadian patent for Olanzapine (IP Factor)